Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
J.P. Morgan, Cowen, SVB Securities and Piper Sandler acted as joint book-running managers of the offering. Cantor and BTIG acted as co-managers.
The securities described above were offered by Biohaven pursuant to effective registration statements on Form S-1, including a prospectus, that were previously filed by Biohaven with the Securities and Exchange Commission (the "
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's Registration Statement on Form S-1 filed with the SEC, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
201-248-0741
Media Contact:
mikebeyer@sambrown.com
312-961-2502
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-301659272.html
SOURCE
BIOHAVEN (BHVN)
Volume | ||
Market Cap | ||
52 Week High | ||
52 Week Low |
Data Provided by Refinitiv. Minimum 15 minutes delayed.